In this CE Concepts webcast, expert faculty will guide learners on how to best evaluate the effect of CAR T-cell and bispecific antibody therapies on the immune system in patients with cancer, utilize best practices for the diagnosis and management of patients receiving T-cell-directing therapies experiencing symptoms consistent with CRS, and Integrate best practices for diagnostic and management approaches for patients receiving T-cell-directing therapies experiencing AEs not consistent with CRS.
In this virtual CE Concepts Grand Rounds, expert faculty will discuss strategies to better integrate diagnostic and prognostic biomarkers for DLBCL, utilize an evidence-based approach for personalizing treatment for patients with R/R DLBCL, and identify and mitigate the impact of AEs associated with novel therapies used in the treatment of patients with R/R DLBCL.
Associate Professor of Clinical Medicine
Weill Cornell Medicine
Division of Hematology & Medical Oncology
New York, NY
In this CEC Oncology recorded Grand Rounds, expert faculty will evaluate the efficacy and safety of first-line PTCL treatments; explore the diagnostic, prognostic, and therapeutic applications of CD30 expression in PTCL subtypes; and discuss strategies to expand collaborative learning and communication that can enhance clinician understanding and proficiency in making informed therapeutic decisions as a treatment team.
In this CE Concepts recorded webcast, expert faculty will guide learners on the implementation of recommended, inclusive, and universal screening techniques and programs for cervical cancer. Faculty will also evaluate the latest efficacy and safety data in different settings for the treatment of cervical cancer as well as incorporate actionable strategies to address disparities and the unique health care of individuals with marginalized sexualities and genders related to cervical cancer screening.
In this CE Concepts recorded Grand Rounds, expert faculty will discuss assessing patients for MF therapy, integrating current and emerging data on JAKis in MF, developing individualized strategies to reduce treatment toxicity and enhance treatment adherence, and evaluating health disparities in MF. The faculty will also provide insight through case examples.
Join our expert faculty for this 60-minute activity designed to help clinicians stay abreast of emerging trial data and evolving treatment guidelines, as well as effectively manage agent-specific AEs, to optimize care for their patients with mUC.
